

October 8, 2025

NANO MRNA Co. Ltd.

To All Members of the Press

NANO MRNA Co., Ltd. Announces
Strategic Alliance with SBI Securities and SBI Shinsei
Corporate Investment

Integrating Capital Markets & Fund Operations with Bio-Venture Management
Pioneering a Revolutionary "Healthcare Conglomerate" Business Model

NANO MRNA Co., Ltd.. (Headquarters: Minato-ku, Tokyo; President & CEO: Shiro Akinaga) announces its strategic alliance to pioneer an innovative business model—a "Healthcare Conglomerate"—through the comprehensive integration of capital markets, fund operations, and bio-venture management capabilities.

Following an extraordinary shareholders' meeting scheduled for December 11, the company will transition to a holding company structure (effective April 1, 2026) and make a full-scale entry into the financial services sector, significantly expanding its business domains. As part of this transformation, NANO MRNA will establish "Nano Bridge Investment", an investment subsidiary, to commence joint fund operations with SBI Shinsei Corporate Investment.

This strategic alliance combines NANO MRNA's deep expertise in bio-healthcare with SBI Securities and SBI Shinsei's proven financial and investment capabilities, driving strategic investments in groundbreaking companies and technologies.

This initiative will revitalize Japan's bio-venture ecosystem while achieving the sustainable growth profile demanded by the Growth Market.

■ Strategic Background and Objectives

Japan's bio-venture sector faces substantial challenges in capital formation and commercialization pathways, with numerous companies struggling to achieve successful IPOs. To address these systemic issues, we are constructing a next-generation healthcare ecosystem that optimizes both fundraising efficiency and accelerated business growth.

■ Revolutionary Business Model Features

- **Unified Investment and Operational Platform**

Seamless integration of capital deployment and operational resources for optimal resource allocation and value creation.

- **Strategic Focus on Next-Generation Technologies and Pipeline Development**

Concentrated investments in transformative technologies including RNA therapeutics, regenerative medicine, AI-driven drug discovery, novel drug delivery systems (DDS), advanced medical devices, and digital health solutions. Our pipeline acquisition and development strategy spans all stages from early discovery through late-stage development, providing comprehensive support throughout the entire value creation cycle.

- **Global Market Expansion Acceleration**

Leveraging extensive international business networks and financial resources to scale healthcare operations globally.

- **Synergy Optimization Framework**

Maximizing business value through strategic collaboration while maintaining portfolio company independence and operational flexibility.

■ Competitive Advantages and Growth Engines

We are establishing a comprehensive ecosystem that integrates investment, operations, and technology—a capability that traditional VCs and pharmaceutical companies struggle to achieve. This platform enables business transformation and accelerated growth, extending far beyond conventional capital provision.

Our differentiated value creation strategies include:

Strategic investments in high-growth-potential companies, targeting returns that significantly exceed dilution effects.

Acquiring companies with undervalued pipelines due to capital constraints through strategic equity transactions, accelerating development timelines, and leveraging our extensive network for strategic partnerships and value maximization.

Providing liquidity solutions to venture capital investors through equity exchanges and portfolio company integrations, creating mutually beneficial transactions for both VC stakeholders and NANO MRNA.

Continuing our "NANO MRNA 2.0" R&D strategy to strengthen and strategically expand our core RNA therapeutics and DDS businesses, establishing the foundational platform for our conglomerate model.

The diagram shows the following structure:

- Nano Holdings** (represented by a box) is connected to the **Target Company** (represented by a circle) via an arrow labeled **Acquisition (Stock Transfer)**.
- Co-GP** (represented by a box) contains two sub-boxes: **NBI** and **SBI**.
- NBI-SBI Fund No.1 Investment Limited Partnership** (represented by a box) is connected to the **Target Company** via an arrow labeled **Investment Cash**.
- The **Target Company** circle is divided into two halves: a blue half labeled **More than 51%** and a white half.

Value

Premium = Option Value

Corporate Value (CV)

Series C

Intrinsic Value (IV)

Series B

Series A

Cash Flow Trend

Nano Holdings Funding

Valuation Recovery

Due to inability to secure cash, option value declines, and intrinsic value also decreases.

■ Key Executive Appointments for Strategic Execution

Satoshi Iino Appointed as Chief Investment Officer (CIO)

Nobuhiro Todokoro Appointed as Chief Growth Officer (CGO)

Chief Investment Officer (CIO): Satoru Iino

Designated President of "Nano Bridge Investment"

Satoru Iino is recognized as one of Japan's premier fund managers, bringing 25 years of exceptional track record in venture capital (VC) and private equity (PE) industries with consistently superior investment performance.

Following his tenure at Hitachi, Ltd., where he spearheaded technology licensing and strategic alliance initiatives with numerous overseas companies—particularly Silicon Valley high-tech ventures during their explosive growth phase—he joined CSK Venture Capital. There, he pioneered early-stage investments in Japan's emerging bio-venture sector while overseeing global venture investments across the United States, Israel, South Korea, and other strategic markets, establishing robust domestic and international networks.

As a founding member of Whiz Partners Co., Ltd., serving as Director, COO, and CIO, he developed innovative investment methodologies utilizing convertible bonds and stock acquisition rights to enhance publicly-listed venture company valuations, achieving outstanding investment performance. In recent years, he has successfully executed large-scale investment projects, including Axcelead, a drug discovery CRO carved out from Takeda Pharmaceutical Company's Shonan Research Center.

Chief Growth Officer (CGO): Nobuhiro Todokoro

Executive Leader for Portfolio Company Value Enhancement and Carve-out Strategies

Nobuhiro Todokoro distinguished himself through numerous senior leadership positions at Nitto Denko Corporation, culminating as Executive Vice President. He orchestrated the company's display materials business transformation from a modest several-hundred-million-yen startup operation into a multi-hundred-billion-yen core business segment.


Even as the industry reached maturity, he consistently pioneered innovative strategies responding to evolving market dynamics, including technological breakthroughs, structural transformation, comprehensive supply chain collaboration (including

competitor partnerships), and intangible asset monetization. His visionary leadership sustained exceptional profitability throughout market cycles.

His collaborative approach—pursuing growth partnerships with customers and suppliers while maintaining comprehensive industry perspective—has earned widespread recognition from stakeholders globally. He continues to maintain an extensive international network.

Following his departure from Nitto Denko, he served as CEO of AXCELEAD, Inc., further expanding his pharmaceutical industry network. Leveraging these comprehensive networks strategically, he is expected to significantly broaden the company's investment portfolio beyond healthcare into diverse high-growth sectors.

(Fig.4) Business Carve-Out from Corporations



■ Four-Year Strategic Targets and Investment Value Proposition

Through this revolutionary business model, we target the following achievements:

- **Assets Under Management (AUM): Approximately ¥30 billion**

Establishing a robust asset foundation through initial fund formation and strategic investment deployment.

- **Portfolio Companies: Approximately 10 companies**

Focused investments in promising enterprises across RNA therapeutics, regenerative medicine, AI drug discovery, and other priority sectors.

- **IPO Generation and M&A Exits: 1–2 companies**

Supporting early-stage growth companies to generate initial public offering success stories.

- **Market Capitalization Target: ¥500–1,000 billion**

[CORRECTED: Updated from ¥50–100 billion to align with Japanese original]

Pursuing sustainable growth through both investment returns and operational business revenue streams.

■ Shareholder Value Creation Commitment

This innovative Healthcare Conglomerate model functions as a comprehensive platform enabling business transformation and accelerated growth, transcending conventional capital provision. By delivering revolutionary healthcare technologies to global markets while generating solid returns, we are committed to maximizing long-term corporate value and shareholder returns.

【Company Profile】

Company Name: NANO MRNA Co., Ltd..

President & CEO: Shiro Akinaga

Headquarters: Atago Green Hills MORI Tower 26F, 2-5-1 Atago, Minato-ku, Tokyo

Website: <https://www.nanomrna.co.jp>

Established: June 1996

Paid-in Capital: ¥166 million

Employees: 20

Business: Pharmaceutical research, development, and manufacturing

【Press Inquiries】

NANO MRNA Co., Ltd..

Corporate Communications Department

Chieko Tsuchiya

TEL: 03-6432-4791 FAX: 03-6432-4794

Email: tsuchiya@nanomrna.co.jp